text:
Basic and Translational Research in Cardiac Repair and Regeneration: JACC State-of-the-Art Review. 78:2092-2105. 2021
Treatment Thresholds and ASCVD Risk. 78:1508-1510. 2021
De-Escalation of DAPT After ACS: Escalating the Odds of Getting It Right. 78:778-780. 2021
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. 78:421-433. 2021
The Coronary Artery Risk Development In Young Adults (CARDIA) Study: JACC Focus Seminar 8/8. 78:260-277. 2021
Atrial Fibrillation and Ischemic Stroke With the Amyloidogenic V122I Transthyretin Variant Among Black Americans. 78:89-91. 2021
Supplemental Association of Clonal Hematopoiesis With Incident Heart Failure. 78:42-52. 2021
Natriuretic Peptide Deficiency in Obese Individuals: Mechanistic Insights From Healthy Organ Donor Cohort. 77:3138-3140. 2021
Chronobiology of Natriuretic Peptides and Blood Pressure in Lean and Obese Individuals. 77:2291-2303. 2021
2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). 77:2053-2150. 2021
Comparison of Management Strategies for Neonates With Symptomatic Tetralogy of Fallot. 77:1093-1106. 2021
Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. 77:559-571. 2021
Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. 76:2982-3021. 2020
Associations of Late Adolescent or Young Adult Cardiovascular Health With Premature Cardiovascular Disease and Mortality. 76:2695-2707. 2020
LVAD Implantation or Heart Transplantation for ECMO-Supported Patients. 76:2575-2576. 2020
Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization. 76:2197-2207. 2020
Sex Differences in Incident and Recurrent Coronary Events and All-Cause Mortality. 76:1751-1760. 2020
Preeclampsia—Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. 76:1690-1702. 2020
Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. 76:1507-1516. 2020
Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art Review. 76:844-857. 2020
Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure. 76:669-679. 2020
Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease. 76:251-264. 2020
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. 75:2297-2308. 2020
Reply: Different Phenotype Characterization in PARAGON-HF: An Unresolved Puzzle in Patients With HFpEF. 75:1501-1502. 2020
Stem Cell–Derived Cardiomyocytes and Beta-Adrenergic Receptor Blockade in Duchenne Muscular Dystrophy Cardiomyopathy. 75:1159-1174. 2020
INCIDENCE AND IMPLICATIONS OF ATRIAL FIBRILLATION IN HYPERTENSION: INSIGHTS FROM THE SPRINT TRIAL. 75:453-453. 2020
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps: JACC State-of-the-Art Review. 75:539-555. 2020
Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review. 75:525-538. 2020
Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES. 75:448-451. 2020
Marijuana Use in Patients With Cardiovascular Disease: JACC Review Topic of the Week. 75:320-332. 2020
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. 75:133-144. 2020
Incident Heart Failure and Long-Term Risk for Venous Thromboembolism. 75:148-158. 2020
Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives. 74:3153-3163. 2019
Quality Assurance for Carotid Stenting in the CREST-2 Registry. 74:3071-3079. 2019
Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. 74:2858-2873. 2019
Ischemic Event Rates in Very-High-Risk Adults. 74:2496-2507. 2019
Trends in Lipid, Lipoproteins, and Statin Use Among U.S. Adults: Impact of 2013 Cholesterol Guidelines. 74:2525-2528. 2019
Improving Communication in Heart Failure Patient Care. 74:1682-1692. 2019
Time to Rethink Prevention of Chronic Kidney Disease?. 74:1477-1479. 2019
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. 74:1167-1176. 2019
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. 74:1177-1186. 2019
Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. 74:617-627. 2019
Home-Based Cardiac Rehabilitation: A Scientific Statement From the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. 74:133-153. 2019
Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. 73:3054-3063. 2019
Effect of Calcium-Channel Blocker Therapy on Radial Artery Grafts After Coronary Bypass Surgery. 73:2299-2306. 2019
Preparing the Cardiovascular Workforce to Care for Oncology Patients: JACC Review Topic of the Week. 73:2226-2235. 2019
Dietary Patterns and Incident Heart Failure in U.S. Adults Without Known Coronary Disease. 73:2036-2045. 2019
Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes in Women. 73:684-693. 2019
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. 73:387-396. 2019
Impact of Chronic Kidney Disease on Outcomes of Myocardial Revascularization in Patients With Diabetes. 73:400-411. 2019
Blood Pressure Assessment in Adults in Clinical Practice and Clinic-Based Research: JACC Scientific Expert Panel. 73:317-335. 2019
Differences in Risk of Sudden Cardiac Death Between Blacks and Whites. 72:2431-2439. 2018
Do Not Smoke, Eat Healthy, and Exercise ∗. 72:2306-2308. 2018
Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk. 72:1763-1773. 2018
2017 ACC/AHA Blood Pressure Treatment Guideline Recommendations and Cardiovascular Risk. 72:1187-1197. 2018
Declining Lung Function and Cardiovascular Risk: The ARIC Study. 72:1109-1122. 2018
Coronary Microvascular Dysfunction and Cardiovascular Risk in Obese Patients. 72:707-717. 2018
Data Science and Cardiac Surgery: Can We Bridge the Gap Between Innovation and Application?. 72:660-661. 2018
Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. 72:636-645. 2018
Ventricular Assist Device Support as a Bridge to Transplantation in Pediatric Patients. 72:402-415. 2018
Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United States. 71:1729-1737. 2018
Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults. 71:1574-1583. 2018
THE CLINICAL SIGNIFICANCE OF TYPE 2 MYOCARDIAL INFARCTION ON OUTCOME AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN DIABETIC KETOACIDOSIS AND HYPEROSMOLAR HYPERGLYCEMIC STATE PATIENTS. 71:A188-A188. 2018
Effect of NT-proBNP–Guided Therapy on All-Cause Mortality in Chronic Heart Failure With Reduced Ejection Fraction. 71:951-952. 2018
Performance of Coronary Risk Scores Among Patients With Chest Pain in the Emergency Department. 71:606-616. 2018
Transplantation of Human Embryonic Stem Cell–Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction. 71:429-438. 2018
Trends in Survival After In-Hospital Cardiac Arrest During Nights and Weekends. 71:402-411. 2018
Potential U.S. Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. 71:109-118. 2018
Coronary Microvascular Dysfunction Identifies Patients at High Risk of Adverse Events Across Cardiometabolic Diseases. 70:2835-2837. 2017
Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. 70:1861-1871. 2017
Palliative Care in Heart Failure: Rationale, Evidence, and Future Priorities. 70:1919-1930. 2017
Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. 70:1875-1886. 2017
Submaximal Blood Pressure Responses to Exercise in Young Adulthood and Long-Term Cardiovascular Health. 70:1941-1943. 2017
Optimizing Cholesterol Treatment in Patients With Muscle Complaints. 70:1290-1301. 2017
Transcatheter Mitral Valve Replacement for Degenerated Bioprosthetic Valves and Failed Annuloplasty Rings. 70:1121-1131. 2017
Association of Estimated Sodium Intake With Adverse Cardiac Structure and Function: From the HyperGEN Study.. 70:715-724. 2017
Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering. 70:766-775. 2017
Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014. 69:2696-2706. 2017
Reproductive Factors and Incidence of Heart Failure Hospitalization in the Women's Health Initiative. 69:2517-2526. 2017
Using Predicted Cardiovascular Disease Risk in Conjunction With Blood Pressure to Guide Antihypertensive Medication Treatment. 69:2446-2456. 2017
Reply: Role of Adiponectin: Important or Null?. 69:1518-1519. 2017
Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. 69:1386-1395. 2017
International Recommendations for Electrocardiographic Interpretation in Athletes. 69:1057-1075. 2017
Big Data, Health Informatics, and the Future of Cardiovascular Medicine. 69:899-902. 2017
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. 69:777-785. 2017
Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. 69:679-691. 2017
Development of Quality Metrics in Ambulatory Pediatric Cardiology. 69:541-555. 2017
Development of a Right Ventricular Outflow Tract Gradient During Upright Exercise: A Hemodynamic Observation. 69:595-597. 2017
Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. 69:367-377. 2017
SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial. 69:395-403. 2017
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. 69:176-185. 2017
The Adipokine-Cardiovascular-Lifestyle Network: Translation to Clinical Practice. 68:1785-1803. 2016
Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease. 68:985-995. 2016
Potential Implications of the Systolic Blood Pressure Intervention Trial in Korea. 67:2832-2834. 2016
Ventricular Assist Device in Acute Myocardial Infarction. 67:1871-1880. 2016
Acute metabolic influences on the natriuretic peptide system in humans. 67:804-812. 2016
U.S. trends in inpatient utilization of fractional flow reserve and percutaneous coronary intervention. 67:732-733. 2016
Generalizability of SPRINT Results to the U.S. Adult Population. 67:463-472. 2016
Selecting Patients for Statin Therapy in Primary Prevention if We Could only Predict the Future. 66:2710-2712. 2015
Enhanced cardiac regenerative ability of stem cells after ischemia-reperfusion injury: Role of human CD34+ cells deficient in microRNA-377. 66:2214-2226. 2015
Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011. 66:1864-1872. 2015
National institutes of health career development awards for cardiovascular physician-scientists recent trends and strategies for success. 66:1816-1827. 2015
Tobacco Use in Peripheral Artery Disease An Economic Drag. 66:1575-1576. 2015
Comprehensive cardiovascular risk factor control improves survival: The BARI 2D trial. 66:765-773. 2015
Improved detection of cardiac allograft vasculopathy: A multi-institutional analysis of functional parameters in pediatric heart transplant recipients. 66:547-557. 2015
Heart Failure as a Newly Approved Diagnosis for Cardiac Rehabilitation: Challenges and Opportunities. 65:2652-2659. 2015
Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 65:1998-2038. 2015
ACC 2015 Core Cardiovascular Training Statement (COCATS 4) (Revision of COCATS 3): A Report of the ACC Competency Management Committee. 65:1721-1723. 2015
COCATS 4 task force 2: Training in preventive cardiovascular medicine. 65:1754-1762. 2015
Short-term mechanical circulatory support: The problem of the uninsured. 65:1062-1063. 2015
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension the SYMPLICITY HTN-3 trial. 65:1314-1321. 2015
Systems Genomics Identifies a Key Role for Hypocretin/Orexin Receptor-2 in Human Heart Failure. 66:2522-2533. 2015
The Gaps in Cardiac Rehabilitation Referral: The Elephant in the Room. 66:2574. 2015
The Role of the Clinical Pharmacist in the Care of Patients with Cardiovascular Disease. 66:2129-2139. 2015
Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. 65:270-277. 2015
The incremental risk of noncardiac surgery on adverse cardiac events following coronary stenting. 64:2730-2739. 2014
Reply: Does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF?. 64:1535-1536. 2014
Cardiomyocyte-specific deletion of Gsk3α mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. 64:696-706. 2014
Paroxysmal AF catheter ablation with a contact force sensing catheter: Results of the prospective, multicenter SMART-AF trial. 64:647-656. 2014
Erratum: Impaired systolic function by strain imaging in heart failure with preserved ejection fraction ( Journal of the American College of Cardiology (2014) 63 (447-456)). 64:335. 2014
Impact of sex on morbidity and mortality rates after lower extremity interventions for peripheral arterial disease: Observations from the blue cross blue shield of Michigan cardiovascular consortium. 63:2525-2530. 2014
Achievement of optimal medical therapy goals for U.S. adults with coronary artery disease: Results from the REGARDS Study (REasons for Geographic and Racial Differences in Stroke). 63:1626-1633. 2014
Impact of mechanical activation, scar, and electrical timing on cardiac resynchronization therapy response and clinical outcomes. 63:1657-1666. 2014
SKELETAL MUSCLE MITOCHONDRIAL FUNCTION AND INTERMITTENT CLAUDICATION IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE FOLLOWING SUPERVISED TREADMILL TRAINING. 63:A2074-A2074. 2014
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. 63:447-456. 2014
Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: Comprehensive analysis to determine the potential role of mitraclip for this unmet need. 63:185-186. 2014
Impact of renal denervation on 24-hour ambulatory blood pressure: Results from SYMPLICITY HTN-3. 64:1071-1078. 2014
Reply. 61:2113. 2013
Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: A report from the BARI 2D trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes). 61:1767-1776. 2013
Risk factor control for coronary artery disease secondary prevention in large randomized trials. 61:1607-1615. 2013
Behavioral mechanisms, elevated depressive symptoms, and the risk for myocardial infarction or death in individuals with coronary heart disease: The regards (reason for geographic and racial differences in stroke) study. 61:622-630. 2013
Cancer genetics and the cardiotoxicity of the therapeutics. 61:267-274. 2013
Declining frequency of ischemia detection using stress myocardial perfusion imaging. 61:1066-1068. 2013
6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. 60:2653-2661. 2012
Long-term outcomes of older diabetic patients after percutaneous coronary stenting in the United States: A report from the national cardiovascular data registry, 2004 to 2008. 60:2280-2289. 2012
Third universal definition of myocardial infarction.. 60:1581-1598. 2012
A randomized controlled phase IIb trial of Beta 1-receptor blockade for chronic degenerative mitral regurgitation. 60:833-838. 2012
Renal failure following ventricular assist device placement. 59:2220. 2012
Evaluation of patients with possible cardiac chest pain: A way out of the jungle. 59:2099-2100. 2012
Angiotensin II plays a critical role in alcohol-induced cardiac nitrative damage, cell death, remodeling, and cardiomyopathy in a protein kinase c/nicotinamide adenine dinucleotide phosphate oxidase-dependent manner. 59:1477-1486. 2012
Prolongation of QTc and risk of stroke: The regards (REasons for Geographic and Racial Differences in Stroke) study. 59:1460-1467. 2012
Characteristics and long-term outcomes of percutaneous revascularization of unprotected left main coronary artery stenosis in the United States: A report from the national cardiovascular data registry, 2004 to 2008. 59:648-654. 2012
Health-related quality of life after carotid stenting versus carotid endarterectomy: Results from CREST (Carotid Revascularization Endarterectomy versus Stenting Trial). 58:1557-1565. 2011
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the American college of cardiology foundation task force on clinical expert consensus documents. 57:2037-2114. 2011
Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 Update: A guideline from the American Heart Association. 57:1404-1423. 2011
Mechanical circulatory support: We are halfway there. 57:1383-1385. 2011
Cardiovascular events in patients with Fabry disease: Natural history data from the Fabry Registry. 57:1093-1099. 2011
Cardiovascular Magnetic Resonance Imaging of the Raghib Complex. 57:e15. 2011
The forgotten left ventricle in right ventricular pressure overload. 57:929-930. 2011
Mechanical rescue of the heart in shock. 57:697-699. 2011
Outcomes of the RESTOR-MV trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve). 56:1984-1993. 2010
Lack of Association between the Trp719Arg Polymorphism in Kinesin-Like Protein-6 and Coronary Artery Disease in 19 Case-Control Studies. 56:1552-1563. 2010
Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: A multicenter trial. 56:290-299. 2010
Single-photon emission computed tomography myocardial perfusion imaging and the risk of sudden cardiac death in patients with coronary disease and left ventricular ejection fraction >35%. 56:206-214. 2010
Angiographic Versus Functional Severity of Coronary Artery Stenoses in the FAME Study. Fractional Flow Reserve Versus Angiography in Multivessel Evaluation. 55:2816-2821. 2010
Survival After Application of Automatic External Defibrillators Before Arrival of the Emergency Medical System. Evaluation in the Resuscitation Outcomes Consortium Population of 21 Million. 55:1713-1720. 2010
Increased Oxidative Stress and Cardiomyocyte Myofibrillar Degeneration in Patients With Chronic Isolated Mitral Regurgitation and Ejection Fraction >60%. 55:671-679. 2010
Stress-Only Myocardial Perfusion Imaging. A New Paradigm. 55:231-233. 2010
Smoking interventions: The beginning of the end or the end of the beginning?. 56:2113-2114. 2010
Late Vascular Healing Response to Stents. New Insights From Optical Coherence Tomography. 55:33-34. 2009
Effect of Moderate Diet-Induced Weight Loss and Weight Regain on Cardiovascular Structure and Function. 54:2376-2381. 2009
Menopause, Age, and Cardiovascular Risk. A Complex Relationship. 54:2374-2375. 2009
ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease). 54:1364-1405. 2009
Regadenoson: A New Myocardial Stress Agent. 54:1123-1130. 2009
The Alpha-1D Is the Predominant Alpha-1-Adrenergic Receptor Subtype in Human Epicardial Coronary Arteries. 54:1137-1145. 2009
Predictors of Cardiac Rehabilitation Referral in Coronary Artery Disease Patients. Findings From the American Heart Association's Get With The Guidelines Program. 54:515-521. 2009
The Effect of Age, Diagnosis, and Previous Surgery in Children and Adults Undergoing Heart Transplantation for Congenital Heart Disease. 54:160-165. 2009
Prediction of Hypertension Improvement After Stenting of Renal Artery Stenosis. Comparative Accuracy of Translesional Pressure Gradients, Intravascular Ultrasound, and Angiography. 53:2363-2371. 2009
The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease. 53:2129-2140. 2009
New Insights Into Effects of Verapamil on Reentrant Circuits During Ventricular Fibrillation in In Vivo Pigs. 53:A122-A122. 2009
Depression and Cardiovascular Health Care Costs Among Women With Suspected Myocardial Ischemia. Prospective Results From the WISE (Women's Ischemia Syndrome Evaluation) Study. 53:176-183. 2009
Skeletal Myoblasts for Cardiac Repair: Act II?. 52:1881-1883. 2008
Metallothionein Suppresses Angiotensin II-Induced Nicotinamide Adenine Dinucleotide Phosphate Oxidase Activation, Nitrosative Stress, Apoptosis, and Pathological Remodeling in the Diabetic Heart. 52:655-666. 2008
The Effects of Medications on Myocardial Perfusion. 52:401-416. 2008
Idiopathic Ventricular Arrhythmias Originating From the Aortic Root. Prevalence, Electrocardiographic and Electrophysiologic Characteristics, and Results of Radiofrequency Catheter Ablation. 52:139-147. 2008
Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease. The TNT (Treating to New Targets) Study. 51:1448-1454. 2008
Randomized Controlled Trial of an Implantable Continuous Hemodynamic Monitor in Patients With Advanced Heart Failure. The COMPASS-HF Study. 51:1073-1079. 2008
Chemical ablation of subendocardium and Purkinje fibers in dogs causes early termination and activation rate slowing of long duration ventricular fibrillation. 51:A4-A5. 2008
Task Force 10: Training in Preventive Cardiovascular Medicine. 51:393-398. 2008
Task Force 8: Training in Heart Failure. Endorsed by the Heart Failure Society of America. 51:383-389. 2008
Comparison of a Radiofrequency-Based Wireless Pressure Sensor to Swan-Ganz Catheter and Echocardiography for Ambulatory Assessment of Pulmonary Artery Pressure in Heart Failure. 50:2375-2382. 2007
Depression, Inflammation, and Incident Cardiovascular Disease in Women With Suspected Coronary Ischemia. The National Heart, Lung, and Blood Institute-Sponsored WISE Study. 50:2044-2050. 2007
C-Reactive Protein Gene Polymorphisms, C-Reactive Protein Blood Levels, and Cardiovascular Disease Risk. 50:1115-1122. 2007
Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura. A Report From the SERF-TTP Research Group and the RADAR Project. 50:1138-1143. 2007
Post-Heart Transplant Diastolic Dysfunction Is a Risk Factor for Mortality. 50:1064-1069. 2007
Preferential Conduction Across the Ventricular Outflow Septum in Ventricular Arrhythmias Originating From the Aortic Sinus Cusp. 50:884-891. 2007
Genetic Testing in Cardiovascular Disease. 50:727-737. 2007
Recombinant Nematode Anticoagulant Protein c2 in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. The ANTHEM-TIMI-32 Trial. 49:2398-2407. 2007
Early Adult Risk Factor Levels and Subsequent Coronary Artery Calcification. The CARDIA Study. 49:2013-2020. 2007
Pretreatment With Intracoronary Enalaprilat Protects Human Myocardium During Percutaneous Coronary Angioplasty. 49:1607-1610. 2007
Prevalence and Severity of Left Atrial Edema Detected by Electron Beam Tomography Early After Pulmonary Vein Ablation. 49:1436-1442. 2007
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update. 49:1230-1250. 2007
Restitution properties immediately preceding conduction block during ventricular fibrillation. 49:14A-14A. 2007
Left Ventricular Eccentric Remodeling and Matrix Loss Are Mediated by Bradykinin and Precede Cardiomyocyte Elongation in Rats With Volume Overload. 49:811-821. 2007
Adiponectin and Cardiovascular Disease. Response to Therapeutic Interventions. 49:531-538. 2007
Detecting Coronary Artery Disease in Left Bundle Branch Block**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. 48:1935-1937. 2006
Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension. Results From Randomized Controlled Pilot Studies. 48:1672-1681. 2006
Beta-Blocker Use and Outcomes Among Hospitalized Heart Failure Patients. 47:2462-2469. 2006
Effect of Caffeine on Ischemia Detection by Adenosine Single-Photon Emission Computed Tomography Perfusion Imaging. 47:2296-2302. 2006
Utility of Impedance Cardiography for the Identification of Short-Term Risk of Clinical Decompensation in Stable Patients With Chronic Heart Failure. 47:2245-2252. 2006
Autologous Myoblast Transplantation for Chronic Ischemic Mitral Regurgitation. 47:2086-2093. 2006
Menopause and Cardiovascular Risk. Cause or Consequence?* * Editorials published in the Journal of American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. 47:1984-1986. 2006
Reentry during ventricular fibrillation is less common intramurally than epicardially in swine. 47:4A-4A. 2006
Sildenafil enhances angiogenesis after mice Hindlimb ischemia. 47:291A-291A. 2006
Three dimensional activation patterns during ventricular fibrillation in swine heart. 47:6A-6A. 2006
Hypertension, menopause, and coronary artery disease risk in the Women's Ischemia Syndrome Evaluation (WISE) study. 47:S50-S58. 2006
Impaired coronary vascular reactivity and functional capacity in women: Results from the NHLBI Women's Ischemia Syndrome Evaluation (WISE) study. 47:S44-S49. 2006
Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Part I: Gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. 47:S4-S20. 2006
Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Part II: Gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. 47:S21-S29. 2006
Some thoughts on the vasculopathy of women with ischemic heart disease. 47:S30-S35. 2006
The value of estimated functional capacity in estimating outcome: Results from the NHBLI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. 47:S36-S43. 2006
Initial clinical experience with regadenoson, a novel selective A 2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. 46:2069-2075. 2005
Intravascular ultrasound for the assessment of an ambiguous left main coronary stenosis [1] (multiple letters). 46:2145-2146. 2005
Ultrafiltration: A new approach toward mechanical diuresis in heart failure. 46:2052-2053. 2005
Perspectives on dyslipidemia and coronary heart disease in women. 46:1628-1635. 2005
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. 46:770-775. 2005
Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties. 45:668-676. 2005
Comparison of human skeletal myoblasts and bone marrow-derived CD133 + progenitors for the repair of infarcted myocardium. 44:458-463. 2004
Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain: Results from the National Heart, Lung, and Blood Institute women's ischemia syndrome evaluation study. 43:2009-2014. 2004
Palliation of allograft vasculopathy with transluminal angioplasty: A decade of experience. 43:1973-1981. 2004
Evidence-based guidelines for cardiovascular disease prevention in women. 43:900-921. 2004
A Randomized, Double-Blind, Placebo-Controlled Trial of Ad5FGF-4 Gene Therapy and its Effect on Myocardial Perfusion in Patients with Stable Angina. 42:1339-1347. 2003
Response to renin-angiotensin system antagonists in hypertensive black subjects [2] (multiple letters). 42:1141-1142. 2003
Nonelectrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans. 42:437-445. 2003
Exercise testing in heart failure: Maximal, submaximal, or both?. 42:123-125. 2003
Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. 41:1078-1083. 2003
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. 41:1148-1155. 2003
Use of fractional flow reserve versus stress perfusion scintigraphy after unstable angina: Effect on duration of hospitalization, cost, procedural characteristics, and clinical outcome. 41:1115-1121. 2003
Effects of intravenous lbutilide on the complexity of activation and the incidence of reentry during ventricular fibrillation in pigs. 41:125A-125A. 2003
Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: A report from the NHLBI-sponsored WISE study. 41:413-419. 2003
Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: Observations from the ESPRIT trial. 41:386-393. 2003
The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs. 40:375-383. 2002
Myocardial creatine kinase expression after left ventricular assist device support. 39:1773-1779. 2002
Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. 39:1374-1379. 2002
Transmural electrical restitution varies transmurally in the in situ swine heart. 39:108A-108A. 2002
Endocardial wave front organization during ventricular fibrillation in humans. 39:109-115. 2002
Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? An angiographic trials pool data experience. 38:624-630. 2001
Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: Initial human clinical experience. 37:1335-1343. 2001
History of anxiety disorders is associated with a decreased likelihood of angiographic coronary artery disease in women with chest pain: The WISE study. 37:780-785. 2001
Amiodarone widens excitable gap during ventricular fibrillation. 37:135A-136A. 2001
Arterial remodeling influences the development of intimal hyperplasia after stent implantation. 37:70-75. 2001
Estrogens, lipids and cardiovascular disease: No easy answers. 37:431-433. 2001
Mechanical cardiac support 2000: current applications and future trial design. June 15-16, 2000 Bethesda, Maryland.. 37:340-370. 2001
Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999: The National Registry of Myocardial Infarction 1, 2 and 3. 36:2056-2063. 2000
Noninvasive characterization of stunned, hibernating, remodeled and nonviable myocardium in ischemic cardiomyopathy. 36:1913-1919. 2000
Weight cycling and high-density lipoprotein cholesterol in women: Evidence of an adverse effect. A report from the NHLBI-sponsored WISE study. 36:1565-1571. 2000
Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect: a report from the NHLBI-sponsored WISE study. Women's Ischemia Syndrome Evaluation Study Group.. 36:1565-1571. 2000
Signaling and expression for mitochondrial membrane proteins during left ventricular remodeling and contractile failure after myocardial infarction. 36:282-287. 2000
Treatment and outcome of myocardial infarction in hospitals with and without invasive capability. 35:371-379. 2000
Evolution of ventricular fibrillation in a canine model. 35:150A-150A. 2000
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction - Results of a multicenter, randomized, placebo-controlled trial: The acute myocardial infarction STudy of ADenosine (AMISTAD) trial. 34:1711-1720. 1999
Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. 34:639-650. 1999
AHA/ACC scientific statement: consensus panel statement. Guide to preventive cardiology for women. American Heart Association/American College of Cardiology.. 33:1751-1755. 1999
Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Results from the pilot phase of the Women's Ischemia Syndrome Evaluation (WISE) study. 33:1469-1475. 1999
Dobutamine stress echocardiography in women with chest pain. Pilot phase data from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). 33:1462-1468. 1999
The Women's Ischemia Syndrome Evaluation (WISE) study: Protocol design, methodology and feasibility report. 33:1453-1461. 1999
Antioxidant vitamins: Sorting out the good and the not so good. 34:1216-1218. 1999
Guide to preventive cardiology for women. 33:1751-1755. 1999
Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. 32:2003-2010. 1998
Risk assessment using single-photon emission computed tomographic technetium-99m sestamibi imaging. 32:57-62. 1998
Influence of payor on use of invasive cardiac procedures and patient outcome after myocardial infarction in the United States. 31:1474-1480. 1998
Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (Recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2). 31:1240-1245. 1998
Handgrip increases endothelin-1 secretion in normotensive young male offspring of hypertensive parents. 31:1362-1366. 1998
Intravascular stents in congenital heart disease: Short- and long-term results from a large single-center experience. 31:661-667. 1998
Correlation between hemodynamic changes and tomographic sestamibi imaging during dipyridamole-induced coronary hyperemia. 31:75-82. 1998
Relation between clinical, angiographic and ischemic findings at baseline and ischemia-related adverse outcomes at 1 year in the asymptomatic cardiac ischemia pilot study. 29:1483-1489. 1997
The prehospital electrocardiogram in acute myocardial infarction: Is its full potential being realized?. 29:498-505. 1997
Ischemic preconditioning during coronary angioplasty [1]. 29:469-470. 1997
Long-term survival of African Americans in the Coronary Artery Surgery Study (CASS). 29:358-364. 1997
Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction >40% after acute myocardial infarction. 29:49-54. 1997
The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: Results of the TIMI III registry ECG ancillary study. 30:133-140. 1997
Asymptomatic Cardiac Ischemia Pilot (ACIP) study: What clinical implications does it have? [2]. 27:1316-1318. 1996
A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. 27:1321-1326. 1996
Cellular basis for improved left ventricular pump function after digoxin therapy in experimental left ventricular failure. 28:495-505. 1996
Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation results of a prospective, randomized multicenter trial. 27:1707-1712. 1996
Arbutamine stress thallium-201 single-photon emission computed tomography using a computerized closed-loop delivery system. Multicenter trial for evaluation of safety and diagnostic accuracy. 26:1159-1167. 1995
Comparison of thallium-201 single-photon emission computed tomography and electrocardiographic response during exercise in patients with normal rest electrocardiographic results. 25:830-836. 1995
Lack of association of recreational cocaine and alcohol use with left ventricular mass in young adults. The coronary artery risk development in young adults (CARDIA) study. 25:895-900. 1995
Asymptomatic cardiac ischemia pilot (ACIP) study: Effects of coronary angioplasty and coronary artery bypass graft surgery on recurrent angina and ischemia. 26:606-614. 1995
Asymptomatic cardiac ischemia pilot (ACIP) study: Impact of anti-ischemia therapy on 12-week rest electrocardiogram and exercise test outcomes. 26:585-593. 1995
Asymptomatic cardiac ischemia pilot (ACIP) study: Outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. 26:594-605. 1995
Better functional status in American than Canadian patients with heart disease: An effect of medical care?. 26:1115-1120. 1995
Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: A CASS registry study. 25:1000-1009. 1995
Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. 26:120-128. 1995
Recurrence of angina after coronary artery bypass surgery: Predictors and prognosis (CASS registry). 26:895-899. 1995
Long-term histologic patency after percutaneous transluminal coronary angioplasty is predicted by the creation of a greater lumen area. 24:1229-1235. 1994
Myocardial bioenergetic abnormalities in a canine model of left ventricular dysfunction. 23:786-793. 1994
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. 23:993-1003. 1994
Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-Week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study. 24:11-20. 1994
Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The studies of left ventricular dysfunction. 23:393-400. 1994
Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the registry of studies of left ventricular dysfunction. 23:1410-1420. 1994
Safety profile of adenosine stress perfusion imaging: Results from the adenoscan multicenter trial registry. 23:384-389. 1994
The Asymptomatic Cardiac Ischemia Pilot (ACIP) study: Design of a randomized clinical trial, baseline data and implications for a long-term outcome trial. 24:1-10. 1994
Radiofrequency ablation for treatment of primary atrial tachycardias. 21:901-909. 1993
Identification of extensive coronary artery disease in women by exercise single-photon emission computed tomographic (SPECT) thallium imaging. 21:1305-1311. 1993
Independent and incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium imaging in coronary artery disease. 22:665-670. 1993
Task force 1: Organization of heart transplantation in the U.S.. 22:8-14. 1993
Task force 4: Function of the heart trnsplant recipient. 22:31-41. 1993
Effect of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the coronary artery surgery study (CASS): 10-Year follow-up. 20:287-294. 1992
Intracoronary ethanol ablation for the treatment of recurrent sustained ventricular tachycardia. 19:159-168. 1992
Nonsurgical closure of femoral pseudoaneurysms complicating cardiac catheterization and percutaneous transluminal coronary angioplasty. 20:610-615. 1992
Prognostic significance of ventricular premature depolarizations measured 1 year after myocardial infraction in patient with early postinfarction asymptomatic ventricular arrhythmia. 20:259-264. 1992
Tomographic myocardial perfusion imaging with technetium-99m teboroxime during adenosine-induced coronary hyperemia: Correlation with thallium-201 imaging. 19:307-312. 1992
Usefulness and limitations of transesophageal echocardiography in the assessment of proximal coronary artery stenosis. 19:572-580. 1992
Vascular pathology of balloon-expandable flexible coil stents in humans. 19:372-381. 1992
A prospective evaluation of intracoronary ethanol ablation of the atrioventricular conduction system. 17:1634-1640. 1991
Amplitude information from Doppler color flow mapping systems: A preliminary study of the power mode. 18:997-1003. 1991
Cardioplegia by way of the coronary sinus for valvular and coronary surgery. 18:628-636. 1991
Intermediate septal accessory pathways: Electrocardiographic characteristics, electrophysiologic observations and their surgical implications. 17:1570-1578. 1991
Relation between functional and anatomic descriptors of coronary artery disease. 17:363-364. 1991
Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. 17:1007-1016. 1991
Single photon emission computed tomography with thallium-201 during adenosine-induced coronary hyperemia: Correlation with coronary arteriography, exercise thallium imaging and two-dimensional echocardiography. 16:1375-1383. 1990
Evidence for central site of action to explain the negative chronotropic effect atropine: Studies on the human transplanted heart. 15:1610-1617. 1990
The thrombolysis in myocardial infarction (TIMI) Trial Phase II: Additional information and perspectives. 15:1188-1192. 1990
Transesophageal Doppler color flow mapping assessment of atrial septal defect. 16:1010-1016. 1990
Effect of exercise level on the ability of thallium-201 tomographic imaging in detecting coronary artery disease: Analysis of 461 patients. 14:1477-1486. 1989
Can two-dimensional echocardiography and Doppler color flow mapping identify the need for tricuspid valve repair?. 14:1266-1274. 1989
Color doppler diagnosis of left ventricular pseudoaneurysm. 13:512. 1989
Combined automatic implantable cardioverter-defibrillator and pacemaker systems: Implantation techniques and follow-up. 13:121-131. 1989
Comparison of endocardial and epicardial programmed stimulation for the induction of ventricular tachycardia. 13:1608-1612. 1989
Coronary artery to right ventricle fistula in heart transplant recipients: A complication of endomyocardial biopsy. 14:258-261. 1989
Doppler color flow mapping in the evaluation of prosthetic mitral and aortic valve function. 13:1561-1571. 1989
Rate dependence of action potential duration and refractoriness in canine ventricular endocardium differs from that of epicardium: Role of the transient outward current. 14:1053-1066. 1989
Relation between myocardial thallium-201 kinetics during exercise and quantitative coronary angiography in patients with one vessel coronary artery disease. 13:1301-1308. 1989
Reproducibility of two-dimensional exercise echocardiography. 14:923-928. 1989
The value of cine nuclear magnetic resonance imaging for assessing regional ventricular function. 14:1721-1729. 1989
Analysis of morbid events and risk factors for death after cardiac transplantation. 11:917-924. 1988
Color-guided Doppler echocardiographic assessment of aortic valve stenosis. 12:441-449. 1988
Exercise training after anterior Q wave myocardial infarction: Harmful or beneficial. 12:373-374. 1988
Intraoperative echocardiography: Who monitors the flood once the flood gates are opened?. 11:1362-1364. 1988
Alpha-myosin heavy chain isoform and atrial size in patients with various types of mitral valve dysfunction: A quantitative study. 9:1024-1030. 1987
Evaluation of aortic insufficiency by Doppler color flow mapping. 9:952-959. 1987
Monitoring the bioenergetics of cardiac allograft rejection using in vivo P-31 nuclear magnetic resonance spectroscopy. 9:1067-1074. 1987
The thrombolysis in myocardial infarction (TIMI) phase II pilot study: Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. 10:51B-64B. 1987
Atrioventricular junctional tachycardia during heart block. 8:657-660. 1986
Differential modulation of autonomic activity by ethmozin and ethacizin (analog of ethmozin) on the canine sinus node and atrioventricular junction. 8:86A-94A. 1986
Serial production of controlled periods of temporary heart block used to unmask and assess latent ventricular automaticity during experimental acute myocardial ischemia. 8:95A-103A. 1986
Pathogenesis of ventricular hypertrophy.. 5:57B-65B. 1985
Late results of surgical and medical therapy for patients with coronary artery disease and depressed left ventricular function. 5:1036-1045. 1985
Morphologie substrates of sudden death: Questions and answers. 5:79B-80B. 1985
Pathogenesis of ventricular hypertrophy. 5:57B-65B. 1985
The plights of the invasive treatment of ischemic heart disease. 5:158-167. 1985
Accurate estimates of absolute left ventricular volumes from equilibrium radionuclide angiographic count data using a simple geometric attenuation correction. 3:789-798. 1984
Ejection fraction determination without planimetry by two-dimensional echocardiography: A new method. 1:1471-1478. 1983


text:
IRS Adopts Taxpayer Bill of Rights
The IRS recently adopted a taxpayer bill of rights. The taxpayer bill of rights takes rights listed in different parts of the Internal Revenue Code and creates broad categories that cover the rights, thus facilitating the ability of taxpayers to track and understand their rights. The bill of rights includes the right to receive quality service, the right to finality of IRS decisions, the right pay no more than the correct amount of tax owed, and the right to a "fair and just" tax system. The adoption of the taxpayer bill of rights comes after lengthy discussions with the Taxpayer Advocate Service and years of advocacy by National Taxpayer Advocate Nina Olson.
The bill of rights will now be listed in IRS Publication 1, which is often included in IRS correspondence with taxpayers. The rights are also available for viewing on the IRS website and will be displayed on posters and signs at IRS offices.
While many practitioners welcome the news, IRS Commissioner John Koskinen stressed that without adequate funding, the taxpayer bill of rights will be difficult to enforce. Commissioner Koskinen plans to continue to reach out to Congress to secure the resources necessary for proper enforcement of the taxpayer bill of rights.
By alliantNational|2014-06-24T22:58:23+06:00June 24th, 2014|Resource Library|Comments Off on IRS Adopts Taxpayer Bill of Rights

redpajama_set_name: RedPajamaCommonCrawl


DC animation is getting dark… With the recent release of Doctor Strange from Marvel we see the recent trend of "magic" making it's way to the public even more. Not to mention something that is becoming a norm..
It is Rated R. Like its predecessor Batman: The Killing Joke. Which I may say did have some disturbing content…( Batman and Batgirl bumping ugly comes to mind ). I am not sure if this is a decision that DC animation studio made lightly. As a parent who watches cartoons with my son I do find this a little troubling. This animated movie have some characters that isn't new to the silver screen.
Constantine forms a team of other supernatural superheroes — Swamp Thing, Deadman, Zatanna, and Etrigan the Demon — to help save the world. We can see the direction this animation is going. Where magic, demons and other things that go bump in the night causing problems. Being Rated-R tells me that there will be some action that may be disturbing. Watching the trailer I done see the dynamics between Constantine and Batman will be the highlight of this animated movie.
Justice League Dark is directed by Jay Oliva (Batman: The Dark Knight Returns) from a story by J.M. DeMatteis and Ernie Altbacker (Green Lantern: The Animated Series). Altbacker also wrote the teleplay. James Tucker (Batman Bad Blood, Batman: Return of the Caped Crusaders) is Supervising Producer. Benjamin Melniker and Michael Uslan are Executive Producers, along with Sam Register.
Justice League Dark will available released on DVD, Blu-ray, and digital in early 2017.